Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- December31 2004
- Volume 11
- Issue 24
News You Can Use
Advertisement
Physician's Money
Digest
According to a reader survey by Simmons Research, about 50% of physicians say they obtain personal finance and investing information from newspapers. According to the Audit Bureau of Circulation, as of November 2003, the following are the top 10 US newspapers, based on average weekday circulation:
Articles in this issue
about 18 years ago
Red vs Blue: Which Side Are You on?about 18 years ago
Use It or Lose Itabout 18 years ago
On the Frugal Sideabout 18 years ago
Check Your Policyabout 18 years ago
PRN: The Roots of Our Prosperityabout 18 years ago
Did You Know?about 18 years ago
Banks: We Hear Youabout 18 years ago
Spitzer's Warsabout 18 years ago
Build Teen Savingsabout 18 years ago
Stop Orders ExplainedAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5